This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsReNeuron Group（RQE1）株式概要Researches, develops, and commercializes cell-based therapies in the United Kingdom. 詳細RQE1 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬過去5年間の収益は年間17.8%増加しました。 リスク分析収益が 100 万ドル未満 ( £249K )キャッシュランウェイが1年未満である 意味のある時価総額がありません ( €2M )株式の流動性は非常に低い すべてのリスクチェックを見るRQE1 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.0347.1k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-17m6m2016201920222025202620282031Revenue UK£6.6kEarnings UK£1.2kAdvancedSet Fair ValueView all narrativesReNeuron Group plc 競合他社co.donSymbol: XTRA:CNWMarket cap: €6.5mSangui Biotech InternationalSymbol: HMSE:SBHMarket cap: €419.8kBellicum PharmaceuticalsSymbol: BST:BPXAMarket cap: €772.4kbioXXmedSymbol: XTRA:T5O0Market cap: €329.8k価格と性能株価の高値、安値、推移の概要ReNeuron Group過去の株価現在の株価UK£0.03452週高値UK£0.1352週安値UK£0.001ベータ0.691ヶ月の変化0%3ヶ月変化-11.69%1年変化-62.22%3年間の変化-97.96%5年間の変化-98.86%IPOからの変化-99.92%最新ニュースお知らせ • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").お知らせ • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.お知らせ • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.New Risk • Nov 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Share price has been highly volatile over the past 3 months (1,168% average daily change). Revenue is less than US$1m (UK£249k revenue, or US$304k). Market cap is less than US$10m (€3.33m market cap, or US$3.55m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year).お知らせ • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023お知らせ • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom最新情報をもっと見るRecent updatesお知らせ • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").お知らせ • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.お知らせ • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.New Risk • Nov 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Share price has been highly volatile over the past 3 months (1,168% average daily change). Revenue is less than US$1m (UK£249k revenue, or US$304k). Market cap is less than US$10m (€3.33m market cap, or US$3.55m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year).お知らせ • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023お知らせ • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United KingdomReported Earnings • May 26Full year 2023 earnings released: UK£0.095 loss per share (vs UK£0.17 loss in FY 2022)Full year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022).お知らせ • May 19ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023Board Change • Apr 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 04+ 1 more updateReNeuron Group plc Appoints Iain Ross as Executive ChairmanReNeuron Group plc announced that Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc.Reported Earnings • Dec 03First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Sep 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Sep 14+ 1 more updateReNeuron Group plc Appoints John Hawkins as Chief Financial OfficerReNeuron Group plc announced the appointment of John Hawkins, ACA, as Chief Financial Officer. Mr. Hawkins joined ReNeuron in October 2014 as Financial Controller and was also appointed Company Secretary in June 2021. Mr. Hawkins is an experienced finance professional with a breadth of experience gained within a variety of businesses, from large PLCs to family-owned SMEs. Mr. Hawkins graduated from university with a 1st class honours degree in industrial chemistry and started his career with KPMG, where he qualified as a Chartered Accountant and worked for the initial part of his career. John Michael Hawkins, aged 56, has been a director or partner of 86 Cathedral Road Rtm Company Limited.Reported Earnings • Aug 18Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 11% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.お知らせ • Aug 17ReNeuron Group plc, Annual General Meeting, Sep 09, 2022ReNeuron Group plc, Annual General Meeting, Sep 09, 2022, at 08:30 Coordinated Universal Time. Location: Covington and Burling LLP Level 54 22 London Greater London United Kingdom Agenda: To receive and adopt the Company's Annual Report and Accounts for the financial year ended 31 March 2022 and the Directors' Report, and the Independent Auditors' Report on those accounts; to reappoint PricewaterhouseCoopers LLP as auditors of the Company; to reappoint as a Director Catherine Isted; to reappoint as a Director Martin Walton; to reappoint as a Director Dr. Mike Owen; and to transact other matters.お知らせ • Aug 01ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022ReNeuron Group plc announced the appointment of Catherine Isted, ACMA, as Chief Executive Officer, effective 1 September 2022. Ms. Isted joined the ReNeuron Board as Chief Financial Officer in October 2021. Following the departure of the former CEO in February this year, Ms. Isted has worked closely with the Executive Management team, led by Iain Ross, to refocus the business around the Group's differentiated exosomes delivery platform.Ms. Isted is an experienced strategic finance professional and chartered management accountant with c.25 years' experience across the Healthcare industry. This includes 12 years at partner level in two leading Healthcare banking teams undertaking multiple Initial Public Offerings and follow-on fundraisings. Within the Healthcare industry, prior to joining ReNeuron, Ms. Isted has also held various in-house financial and strategic roles spanning Corporate Development, Investor Relations and Financial Planning and Analysis. Ms. Isted joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was instrumental in raising in excess of £110 million and supporting potential board level strategic opportunities. She has also held senior research analyst and equity sales positions in the Healthcare teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. Ms. Isted holds a 1st Class chemistry degree along with experience as a bench scientist, before moving into finance and training as an accountant at Merck.Reported Earnings • Jul 05Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 92%, compared to a 29% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.お知らせ • Jun 21ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022ReNeuron Group plc announced that they will report fiscal year 2022 results on Jul 04, 2022お知らせ • Jun 11ReNeuron Group plc, Annual General Meeting, Jul 14, 2022ReNeuron Group plc, Annual General Meeting, Jul 14, 2022, at 10:00 Coordinated Universal Time. Location: offices of Ashurst LLP, The London Fruit & Wool Exchange, 1 Duval Square, London E1 6PW London United Kingdomお知らせ • Feb 12ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022ReNeuron Group plc announced that Olav Hellebø is standing down as CEO of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.お知らせ • Feb 11ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive DirectorReNeuron Group plc announced that Olav Hellebø is standing down as executive director of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.Reported Earnings • Dec 02First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Over the next year, revenue is forecast to grow 55%, compared to a 80% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.Recent Insider Transactions • Oct 22Board Member recently bought €59k worth of stockOn the 20th of October, Barbara Staehelin bought around 43k shares on-market at roughly €1.37 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Aug 22Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year.Reported Earnings • Jul 09Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 13+ 1 more updateReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial OfficerReNeuron Group plc announces that Michael Hunt, an executive director of the Company and its current Chief Financial Officer, has resigned from the Company in order to pursue other projects. Mr. Hunt joined the Board in early 2001 and will remain with the Company until the end of May to facilitate an orderly transition to his successor, when appointed. The Company has initiated a search for Mr. Hunt's replacement and a further announcement will be made in due course.Is New 90 Day High Low • Jan 08New 90-day high: €1.16The company is up 15% from its price of €1.01 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period.Is New 90 Day High Low • Dec 16New 90-day low: €0.80The company is down 12% from its price of €0.91 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Reported Earnings • Nov 26First half 2021 earnings released: UK£0.22 loss per shareFirst half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 24New 90-day low: €0.85The company is down 24% from its price of €1.12 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Oct 03ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020ReNeuron Group plc announced that they will report first half, 2021 results on Nov 10, 2020お知らせ • Aug 25ReNeuron Group plc Auditor Raises 'Going Concern' DoubtReNeuron Group plc filed its Annual on Aug 19, 2020 for the period ending Mar 31, 2020. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.株主還元RQE1DE BiotechsDE 市場7D0%2.9%-0.7%1Y-62.2%-6.3%2.0%株主還元を見る業界別リターン: RQE1過去 1 年間で-6.3 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: RQE1は、過去 1 年間で2 % のリターンを上げたGerman市場を下回りました。価格変動Is RQE1's price volatile compared to industry and market?RQE1 volatilityRQE1 Average Weekly Movementn/aBiotechs Industry Average Movement8.9%Market Average Movement5.9%10% most volatile stocks in DE Market13.0%10% least volatile stocks in DE Market2.8%安定した株価: RQE1の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のRQE1のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199726n/awww.reneuron.comもっと見るReNeuron Group plc 基礎のまとめReNeuron Group の収益と売上を時価総額と比較するとどうか。RQE1 基礎統計学時価総額€2.25m収益（TTM）-€5.91m売上高(TTM)€290.24k7.7xP/Sレシオ-0.4xPER（株価収益率RQE1 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RQE1 損益計算書（TTM）収益UK£249.00k売上原価UK£3.65m売上総利益-UK£3.40mその他の費用UK£1.67m収益-UK£5.07m直近の収益報告Sep 30, 2023次回決算日May 30, 2024一株当たり利益（EPS）-0.089グロス・マージン-1,367.47%純利益率-2,037.35%有利子負債／自己資本比率0%RQE1 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/04 05:23終値2024/02/05 00:00収益2023/09/30年間収益2023/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ReNeuron Group plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関David Paul St. JohnsonAllenby Capital LimitedSoo RomanoffEdison Investment ResearchJason McCarthyMaxim Group2 その他のアナリストを表示
お知らせ • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").
お知らせ • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
お知らせ • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.
New Risk • Nov 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Share price has been highly volatile over the past 3 months (1,168% average daily change). Revenue is less than US$1m (UK£249k revenue, or US$304k). Market cap is less than US$10m (€3.33m market cap, or US$3.55m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year).
お知らせ • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023
お知らせ • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom
お知らせ • Aug 31ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation").
お知らせ • Apr 17ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
お知らせ • Jan 30ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations.
New Risk • Nov 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Share price has been highly volatile over the past 3 months (1,168% average daily change). Revenue is less than US$1m (UK£249k revenue, or US$304k). Market cap is less than US$10m (€3.33m market cap, or US$3.55m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year).
お知らせ • Oct 27ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023
お知らせ • Jul 25ReNeuron Group plc, Annual General Meeting, Aug 22, 2023ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom
Reported Earnings • May 26Full year 2023 earnings released: UK£0.095 loss per share (vs UK£0.17 loss in FY 2022)Full year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022).
お知らせ • May 19ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023
Board Change • Apr 20High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 04+ 1 more updateReNeuron Group plc Appoints Iain Ross as Executive ChairmanReNeuron Group plc announced that Iain Ross, who has been on the Board since July 2021, has been appointed as Executive Chairman and will lead a restructuring of the business, with further announcements to be made in due course. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc.
Reported Earnings • Dec 03First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Sep 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Sep 14+ 1 more updateReNeuron Group plc Appoints John Hawkins as Chief Financial OfficerReNeuron Group plc announced the appointment of John Hawkins, ACA, as Chief Financial Officer. Mr. Hawkins joined ReNeuron in October 2014 as Financial Controller and was also appointed Company Secretary in June 2021. Mr. Hawkins is an experienced finance professional with a breadth of experience gained within a variety of businesses, from large PLCs to family-owned SMEs. Mr. Hawkins graduated from university with a 1st class honours degree in industrial chemistry and started his career with KPMG, where he qualified as a Chartered Accountant and worked for the initial part of his career. John Michael Hawkins, aged 56, has been a director or partner of 86 Cathedral Road Rtm Company Limited.
Reported Earnings • Aug 18Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 11% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
お知らせ • Aug 17ReNeuron Group plc, Annual General Meeting, Sep 09, 2022ReNeuron Group plc, Annual General Meeting, Sep 09, 2022, at 08:30 Coordinated Universal Time. Location: Covington and Burling LLP Level 54 22 London Greater London United Kingdom Agenda: To receive and adopt the Company's Annual Report and Accounts for the financial year ended 31 March 2022 and the Directors' Report, and the Independent Auditors' Report on those accounts; to reappoint PricewaterhouseCoopers LLP as auditors of the Company; to reappoint as a Director Catherine Isted; to reappoint as a Director Martin Walton; to reappoint as a Director Dr. Mike Owen; and to transact other matters.
お知らせ • Aug 01ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022ReNeuron Group plc announced the appointment of Catherine Isted, ACMA, as Chief Executive Officer, effective 1 September 2022. Ms. Isted joined the ReNeuron Board as Chief Financial Officer in October 2021. Following the departure of the former CEO in February this year, Ms. Isted has worked closely with the Executive Management team, led by Iain Ross, to refocus the business around the Group's differentiated exosomes delivery platform.Ms. Isted is an experienced strategic finance professional and chartered management accountant with c.25 years' experience across the Healthcare industry. This includes 12 years at partner level in two leading Healthcare banking teams undertaking multiple Initial Public Offerings and follow-on fundraisings. Within the Healthcare industry, prior to joining ReNeuron, Ms. Isted has also held various in-house financial and strategic roles spanning Corporate Development, Investor Relations and Financial Planning and Analysis. Ms. Isted joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was instrumental in raising in excess of £110 million and supporting potential board level strategic opportunities. She has also held senior research analyst and equity sales positions in the Healthcare teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. Ms. Isted holds a 1st Class chemistry degree along with experience as a bench scientist, before moving into finance and training as an accountant at Merck.
Reported Earnings • Jul 05Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 92%, compared to a 29% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
お知らせ • Jun 21ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022ReNeuron Group plc announced that they will report fiscal year 2022 results on Jul 04, 2022
お知らせ • Jun 11ReNeuron Group plc, Annual General Meeting, Jul 14, 2022ReNeuron Group plc, Annual General Meeting, Jul 14, 2022, at 10:00 Coordinated Universal Time. Location: offices of Ashurst LLP, The London Fruit & Wool Exchange, 1 Duval Square, London E1 6PW London United Kingdom
お知らせ • Feb 12ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022ReNeuron Group plc announced that Olav Hellebø is standing down as CEO of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.
お知らせ • Feb 11ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive DirectorReNeuron Group plc announced that Olav Hellebø is standing down as executive director of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.
Reported Earnings • Dec 02First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Over the next year, revenue is forecast to grow 55%, compared to a 80% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.
Recent Insider Transactions • Oct 22Board Member recently bought €59k worth of stockOn the 20th of October, Barbara Staehelin bought around 43k shares on-market at roughly €1.37 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Aug 22Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year.
Reported Earnings • Jul 09Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 13+ 1 more updateReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial OfficerReNeuron Group plc announces that Michael Hunt, an executive director of the Company and its current Chief Financial Officer, has resigned from the Company in order to pursue other projects. Mr. Hunt joined the Board in early 2001 and will remain with the Company until the end of May to facilitate an orderly transition to his successor, when appointed. The Company has initiated a search for Mr. Hunt's replacement and a further announcement will be made in due course.
Is New 90 Day High Low • Jan 08New 90-day high: €1.16The company is up 15% from its price of €1.01 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: €0.80The company is down 12% from its price of €0.91 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Reported Earnings • Nov 26First half 2021 earnings released: UK£0.22 loss per shareFirst half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 24New 90-day low: €0.85The company is down 24% from its price of €1.12 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Oct 03ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020ReNeuron Group plc announced that they will report first half, 2021 results on Nov 10, 2020
お知らせ • Aug 25ReNeuron Group plc Auditor Raises 'Going Concern' DoubtReNeuron Group plc filed its Annual on Aug 19, 2020 for the period ending Mar 31, 2020. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
